Craft

Ypsomed

Stock Price

CHF410.5

2024-10-29

Market Capitalization

CHF5.6 B

2024-10-29

Revenue

CHF731 M

FY, 2026

Ypsomed Summary

Company Summary

Overview
Ypsomed is a company that develops, manufactures, and sells injection and infusion systems for pharmaceutical and biotechnology companies. It operates through Ypsomed Diabetes Care, Ypsomed Delivery Systems, and Others segments. The Ypsomed Delivery Systems segment offers various injection systems, such as pen injectors, auto injectors and dual-chamber pens, as well as insulin pens, other diabetes pens, pens for growth hormones and other pens. The Ypsomed Diabetes Care segment sells and trades in insulin pumps, infusion sets, pen needles, blood glucose monitoring systems, accessories and other day-to-day items for diabetics. The Others segment offers precision turned parts.
Type
Public
Status
Active
Founded
2003
HQ
Burgdorf, CH | view all locations
Website
https://www.ypsomed.com/en/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • Simon Michel

    Simon Michel, Chief Executive Officer

  • Frank Mengis

    Frank Mengis, Chief Operating Officer (COO)

    LocationsView all

    22 locations detected

    • Burgdorf, BE HQ

      Switzerland

      Brunnmattstrasse 6

    • Mona Vale, NSW

      Australia

      602/20 Bungan St

    • Wien, Wien

      Austria

      Am Europl. 2

    • Anderlecht, Brussels Hoofdstedelijk Gewest

      Belgium

      Researchdreef 12

    • Pointe-Claire, QC

      Canada

      1 Avenue Holiday #647

    • 北京市

      China

      8 North Dongsanhuan Road, 北京市 China

    and 16 others

    Ypsomed Financials

    Summary Financials

    Revenue (FY, 2026)
    CHF731.0M
    Gross profit (FY, 2026)
    CHF480.5M
    Net income (FY, 2026)
    CHF221.9M
    Cash (FY, 2026)
    CHF28.6M
    EBIT (FY, 2026)
    CHF246.1M
    Enterprise value
    $5.8B

    Footer menu